|Bid||259.06 x 800|
|Ask||259.28 x 900|
|Day's Range||258.81 - 262.45|
|52 Week Range||229.40 - 277.29|
|Beta (5Y Monthly)||0.61|
|PE Ratio (TTM)||39.38|
|Earnings Date||Nov 02, 2022 - Nov 07, 2022|
|Forward Dividend & Yield||3.48 (1.35%)|
|Ex-Dividend Date||Sep 08, 2022|
|1y Target Est||274.55|
Subscribe to Yahoo Finance Plus to view Fair Value for BDX
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Value Strategy” second quarter 2022 investor letter. A copy of the letter can be downloaded here. In the second quarter, the strategy underperformed its Russell 1000 Value benchmark Index. The second quarter was highly volatile due to changes in interest rates, fears of recession, and […]
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration agreement with Labcorp (NYSE: LH), a leading global life sciences company, creating a framework to develop, manufacture, market and commercialize flow cytometry-based companion diagnostics (CDx) intended to match patients with life-changing treatments for cancer and other diseases.
Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced that it has commenced tender offers to purchase for cash the debt securities issued by the Company listed in the table below (collectively, the "Securities" and each a "series").